Let us imagine a world where we are no longer witnessing blood shortages, transfusion delays, and rare blood-type incompatibilities, as they mostly serve as life-threatening barriers.
In November 2023, researchers from the UK launched the “RESTORE trial”, world’s first clinical study to transfuse lab-grown red blood cells into human volunteers. The results were published in the journal “Nature Biotechnology”, where it was demonstrated that the synthetic red blood cells functioned normally and they also survived significantly longer in circulation compared to the standard donor cells. This property can assist in fewer transfusions for patients with chronic anemia or blood disorders.
The process here involves extraction of stem cells from a donor’s blood and then culturing them in controlled lab conditions towards production of RBCs in bioreactors. This approach ensures precise quality control, and also it does eliminate the risk of infectious disease transmission, alongwith providing a life-saving solution for patients with rare blood types who often face delays in finding compatible donors.
Significant Applications:
-
Synthetic blood can be used in emergency trauma care where matched blood is unavailable.
-
Also can be used in case of chronic transfusion patients suffering from conditions like sickle cell disease/thalassemia
-
Military/remote area medical use, where long shelf life and portability plays a critical role
While synthetic blood is still in early stages of clinical development and costly at the moment to produce at scale, the long-term implications are profound.
– Can synthetic blood will be able to reduce global dependence on traditional blood donations?
– If synthetic blood becomes viable at scale, should its use be prioritized for specific populations (e.g., rare blood types, military, low-resource regions)?